RxDoctor Payments Data

Jill Hall, MD

Gynecology · Ventura, CANPI 1265607204

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,748 of the $6,283 with a category attached, or 75.6%. Medtronic accounts for 71.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $2,830 and has fallen 64.7% since, to $999 in 2025.

$6,283in general payments, 2019–2025

Across 121 payments — averaging $51.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Intuitive Surgical$347
  • Axonics, Inc.$329
  • Coloplast$210
  • Valencia Technologies Corporation$132
  • Amarin Pharma, Inc.$125
  • plus $660 from 11 others

What the payments were for

  • Travel & lodging$1,26620%
  • Food & beverage$4,74876%
  • Education$2694%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,283 in reported general payments places this provider in the 85th percentile of 247 gynecology providers in California.

See all gynecology providers in California

Medicare billing

Part B allowed, 2024
$193,062
Medicare patients
399
Services billed
2,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron236$155,443
MyrbetriqMirabegron190$103,445
Estradiol289$16,202
PremarinEstrogens, Conjugated20$8,460
Mirabegron ErMirabegron18$7,656
Fosfomycin Tromethamine17$3,259
Darifenacin ErDarifenacin Hydrobromide15$1,971
Tolterodine Tartrate ErTolterodine Tartrate31$1,550
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$1,066
Heparin SodiumHeparin Sodium,porcine25$796
Solifenacin Succinate23$754
Ketoconazole15$580
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip32$406
Cephalexin43$319
Bethanechol Chloride22$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$50$155,443236 claims
Astellas Pharma US IncMyrbetriq$74$103,445190 claims
PfizerPremarin$97$8,46020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 gynecology providers in California.

Other gynecology in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →